REAL WORLD EVENT DISCUSSIONS

Scripps Team Awarded $1.8M Grant to Develop Drugs for Heart Disease, RA (topic: public money, private profit)

POSTED BY: 1KIKI
UPDATED: Monday, January 30, 2017 19:46
SHORT URL:
VIEWED: 1315
PAGE 1 of 1

Monday, January 30, 2017 7:46 PM

1KIKI

Goodbye, kind world (George Monbiot) - In common with all those generations which have contemplated catastrophe, we appear to be incapable of understanding what confronts us.


Here's the public money: $1.8 million from the National Institute of General Medical Sciences of the National Institutes of Health.
The private profit will come in the form of IP, patents, and licenses.


http://www.dddmag.com/news/2017/01/scripps-team-awarded-18m-grant-deve
lop-drugs-heart-disease-ra



Scripps Team Awarded $1.8M Grant to Develop Drugs for Heart Disease, RA

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.8 million from the National Institute of General Medical Sciences of the National Institutes of Health to develop a series of drug candidates for a number of diseases, including heart disease, rheumatoid arthritis and several neurodegenerative disorders.

The co-principal investigators of the three-year project are TSRI Professor William R. Roush and Associate Professor Derek Duckett.

“This is an exciting project, and I think our combined efforts are well-positioned to make significant progress over the next three years,” said Roush.

The new project will focus on an enzyme known as ASK1, which is involved in mediating cell survival and programmed cell death, or apoptosis. ASK1 is part of a larger family of mitogen-activated protein kinases (MAP kinases), enzymes that help control a cell’s response to stress. A number of studies have shown that animal models lacking ASK1 have decreases in the size of myocardial infarctions (heart attacks) and a marked resistance to heart cell death.

“ASK1 has been highlighted as a therapeutic target in several stress-related diseases and we expect that inhibitors of its activity will provide significant benefit in multiple disease states,” Duckett said.

Under a previous grant, Duckett and his colleagues completed a high throughput screening campaign aimed at identifying the best lead molecules to target ASK1, ultimately producing a series of small molecule inhibitor candidates from six different structural classes.

“This new grant is the result of another fruitful collaboration between Derek’s lab and mine,” Roush noted. “The starting point for our effort to develop a selective and brain penetrant ASK1 inhibitor originated from high throughput screening, molecular modelling for compound design, and initial rounds of synthesis and testing.”

The optimization strategy going forward, Duckett explained, will focus on developing inhibitor properties sufficient for use in pre-clinical testing, and ultimately, in safety assessment and clinical trials.


NOTIFY: Y   |  REPLY  |  REPLY WITH QUOTE  |  TOP  |  HOME  

YOUR OPTIONS

NEW POSTS TODAY

USERPOST DATE

OTHER TOPICS

DISCUSSIONS
Dutch rethink Christianity for a doubtful world
Sat, June 15, 2024 15:00 - 111 posts
Fiscal Cliff Avoided. Woopee?
Sat, June 15, 2024 14:55 - 26 posts
India
Sat, June 15, 2024 14:53 - 94 posts
The AI in a box
Sat, June 15, 2024 14:50 - 194 posts
Intercepted communications between Russia, Trump
Sat, June 15, 2024 14:29 - 120 posts
State of the Nation - Hungary
Sat, June 15, 2024 14:20 - 4 posts
BRICS summit 2023... and who's on America's shit list
Sat, June 15, 2024 13:56 - 17 posts
In the garden, and RAIN!!! (2)
Sat, June 15, 2024 13:21 - 3911 posts
What kind of superpower could China be?
Sat, June 15, 2024 13:18 - 15 posts
United States 2028 Presidential Election...it will still be United, continue being a Union?
Sat, June 15, 2024 12:26 - 25 posts
Mid-Term 2026 US Elections
Sat, June 15, 2024 12:22 - 24 posts
Japanese Culture, S.Korea movies are now outselling American entertainment products
Sat, June 15, 2024 12:20 - 27 posts

FFF.NET SOCIAL